But lower food volume means less bulk moving through the intestines, which can further slow transit time and contribute to c onstipation symptoms
oral formulation 2019), and tirzepatide (2022)the latter being a dual GIP/GLP-1 agonist ( Table 2 ) ( Table 2 Overview of GLP-1 receptor agonists (GLP-1RAs) approved by the EMA and/or FDA, with year of authorization and main therapeutic indications
Semaglutide has more published data on inflammatory marker reduction
We reviewed the current state of evidence across the research disciplines of basic or fundamental science, clinical and health services research, and person-centred equity science, and highlighted important knowledge gaps that offer opportunities for future research
Janelle M
[DOI] [PubMed] [Google Scholar] 311.Heyworth P.G., Bohl B.P., Bokoch G.M., Curnutte J.T